Clinical predictors of Dimethyl Fumarate response in multiple sclerosis: a real life multicentre study.
ConclusionsWe confirm that DMF shows a good efficacy in both naïve patients and patients switching from other first-line DMTs, especially in patients with early onset of disease. Higher baseline EDSS was a risk factor for discontinuing DMF therapy, while shorter disease duration was protective for both EDSS progression and NEDA-3 status maintenance.
Source: Multiple Sclerosis and Related Disorders - Category: Neurology Source Type: research
More News: Clinical Trials | Disability | Italy Health | Liver | Multiple Sclerosis | Neurology | Pancreas | Pregnancy | Study | Urology & Nephrology